<DOC>
	<DOCNO>NCT03095079</DOCNO>
	<brief_summary>The incidence Melanoma rapidly growthing , China , dacarbazine combine cisplatin conmendly use first-line chemotherapy metastatic melanoma . But response rate survival result limited.This trial aim add safe effective anti-angiogenesis drug , Human-recombinant endostatin , find new strategy may extend PFS OS tolerate toxicity .</brief_summary>
	<brief_title>Rh-endostatin Combination With Dacarbazine Cisplatin First Line Therapy Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>1 . Histologically confirm melanoma metastasis receive systemic treatment . 2.At least one measurable site ( diameter≥1cm ) disease ( RECIST 1.1 ) . 3.Estimated life expectancy 12 week great 4 . ECOG performance status 0 , 1 5.Adequate organ function 6.Without symptom brain metastasis stable neurofunctions 1 . Pregnant lactation woman 2 . Acute infection without control . 3 . Heart disease history , cardiac function class≥NYHA II . 4 . HIV positive chronic HBV/HCV active stage . 5 . Brain metastasis primary tumor positive symptom 6 . Need antiepileptic treatment 7 . Organ transplantation history 8 . Hemorrhagic tendency relate history 9 . Renal dialysis patient 10 . Diagnosis second malignancy within last 3 year , except adequately treat . 11 . Current treatment another clinical trial 12 . The improper situation investigator judge .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>endostar</keyword>
	<keyword>dacarbazine</keyword>
	<keyword>cisplatin</keyword>
</DOC>